{
    "id": "aba52bdc-99f1-4e08-a0c6-f7ec5176a178",
    "indications": {
        "text": "vyloy , combination fluoropyrimidine- platinum-containing chemotherapy , indicated first-line treatment adults locally advanced unresectable metastatic human epidermal growth factor receptor 2 ( her2 ) \u2011negative gastric gastroesophageal junction ( gej ) adenocarcinoma whose tumors claudin ( cldn ) 18.2 positive determined fda-approved test [ ( 2.1 ) ( 14 ) ] .",
        "doid_entities": [
            {
                "text": "adenocarcinoma (DOID:299)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_299"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "\u2022 administer intravenous infusion . administer vyloy intravenous push bolus . ( 2.6 ) \u2022 recommended first dose vyloy 800 mg/m 2 followed 600 mg/m 2 every 3 weeks 400 mg/m 2 every 2 weeks . ( 2.3 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "adverseReactions": "none .",
    "ingredients": [
        {
            "name": "ZOLBETUXIMAB",
            "code": "TF5MPQ8WGY",
            "drugbank_id": "https://go.drugbank.com/drugs/DB15118"
        },
        {
            "name": "ARGININE",
            "code": "94ZLA3W45F",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_29016"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17992"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_53426"
        },
        {
            "name": "PHOSPHORIC ACID",
            "code": "E4GA8884NN",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_26078"
        }
    ],
    "organization": "Astellas Pharma US, Inc.",
    "name": "VYLOY",
    "effectiveTime": "20250324",
    "indications_original": "VYLOY, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)\u2011negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are claudin (CLDN) 18.2 positive as determined by an FDA-approved test [see Dosage and Administration (2.1) and Clinical Studies (14)].",
    "contraindications_original": "\u2022 Administer by intravenous infusion only . Do not administer VYLOY as an intravenous push or bolus. ( 2.6 ) \u2022 The recommended first dose of VYLOY is 800\u00a0mg/m 2 followed by 600\u00a0mg/m 2 every 3 weeks or 400 mg/m 2 every 2 weeks. ( 2.3 )",
    "adverseReactions_original": "None.",
    "drug": [
        {
            "name": "VYLOY",
            "drugbank_id": "https://go.drugbank.com/drugs/DB15118"
        }
    ]
}